MX2019005782A - Prevencion y/o tratamiento de lesion aguda de riñon inducida por contraste. - Google Patents

Prevencion y/o tratamiento de lesion aguda de riñon inducida por contraste.

Info

Publication number
MX2019005782A
MX2019005782A MX2019005782A MX2019005782A MX2019005782A MX 2019005782 A MX2019005782 A MX 2019005782A MX 2019005782 A MX2019005782 A MX 2019005782A MX 2019005782 A MX2019005782 A MX 2019005782A MX 2019005782 A MX2019005782 A MX 2019005782A
Authority
MX
Mexico
Prior art keywords
kidney injury
contrast
acute kidney
induced acute
prevention
Prior art date
Application number
MX2019005782A
Other languages
English (en)
Inventor
Kazanchyan Anna
CORNELIO Shalini
Original Assignee
Saghmos Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Saghmos Therapeutics Inc filed Critical Saghmos Therapeutics Inc
Publication of MX2019005782A publication Critical patent/MX2019005782A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se proporcionan métodos para prevenir, reducir y/o tratar lesión aguda de riñón inducida por contraste, los cuales incluyen administrar un inhibidor de oxidación de ácidos grasos a un paciente en necesidad de lo mismo. También se proporcionan métodos que involucran el uso de trimetazidina o sales farmacéuticamente aceptables de la misma para la prevención y/o tratamiento de lesión aguda de riñón inducida por contraste. También se proporcionan métodos para prevenir y/o tratar lesión aguda de riñón inducida por contraste, los cuales incluyen administración de uno o más de trimetazidina, etomoxir, oxfenicina, perhexilina, mildronato o ranolazina o una sal farmacéuticamente aceptable de cualquiera de los precedentes.
MX2019005782A 2016-11-21 2017-11-21 Prevencion y/o tratamiento de lesion aguda de riñon inducida por contraste. MX2019005782A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662424771P 2016-11-21 2016-11-21
PCT/US2017/062771 WO2018094387A1 (en) 2016-11-21 2017-11-21 Prevention and/or treatment of contrast-induced acute kidney injury

Publications (1)

Publication Number Publication Date
MX2019005782A true MX2019005782A (es) 2019-08-29

Family

ID=62144125

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019005782A MX2019005782A (es) 2016-11-21 2017-11-21 Prevencion y/o tratamiento de lesion aguda de riñon inducida por contraste.

Country Status (6)

Country Link
US (3) US20180140599A1 (es)
EP (2) EP3525771A4 (es)
JP (3) JP7474463B2 (es)
CA (1) CA3044270A1 (es)
MX (1) MX2019005782A (es)
WO (1) WO2018094387A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3044270A1 (en) 2016-11-21 2018-05-24 Saghmos Therapeutics, Inc. The use of trimetazidine in the prevention and/or treatment of contrast-induced acute kidney injury____
US10946011B2 (en) * 2018-02-19 2021-03-16 Martin Pharmaceuticals, Inc. Stable oral liquid formulation of trimetazidine

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2490963B1 (fr) * 1980-09-30 1986-04-18 Science Union & Cie Nouvelle composition therapeutique a action anti-ischemique contenant de la trimethoxy 2, 3, 4-benzyl 1-piperazine
US20080059228A1 (en) 2004-04-24 2008-03-06 Christopher Bossi Operation Of A Remote Medication Management System
WO2008057534A2 (en) 2006-11-07 2008-05-15 University Of Vermont And State Agricultural College Methods and compositions for organ protection
CA2679975A1 (en) 2007-03-09 2008-09-18 Symcopeia Company Therapy for hyperglycemia, related disorders and erectile dysfunction
WO2009066315A2 (en) 2007-08-08 2009-05-28 Usv Limited Sustained release compositions of trimetazidine and process for preparation thereof
WO2009034541A2 (en) 2007-09-11 2009-03-19 Ranbaxy Laboratories Limited Controlled release pharmaceutical dosage forms of trimetazidine
WO2009088860A2 (en) 2007-12-31 2009-07-16 Inotek Pharmaceuticals Corporation A method of preventing contrast-induced nephropathy
DK2262520T3 (en) * 2008-02-26 2017-08-07 Univ Cornell COMPOSITIONS FOR PREVENTION AND TREATMENT OF Kidney Injury
WO2011041478A1 (en) 2009-10-02 2011-04-07 Baxter International Inc. Hematopoietic stem cells for use in the treatment of a kidney injury
US9271952B2 (en) 2011-10-11 2016-03-01 Complexa, Inc. Compositions and methods for treating nephropathy
FR2986431B1 (fr) 2012-02-03 2017-03-17 Servier Lab Composition pharmaceutique a liberation prolongee de trimetazidine, son procede de fabrication et son utilisation dans des traitements therapeutiques
CA3044270A1 (en) 2016-11-21 2018-05-24 Saghmos Therapeutics, Inc. The use of trimetazidine in the prevention and/or treatment of contrast-induced acute kidney injury____
WO2018129045A1 (en) 2017-01-03 2018-07-12 Saghmos Therapeutics, Inc. Methods of improving patient compliance to treat contrast-induced injury

Also Published As

Publication number Publication date
US11123345B2 (en) 2021-09-21
US11986473B2 (en) 2024-05-21
JP2019535830A (ja) 2019-12-12
US20180140599A1 (en) 2018-05-24
EP3525771A4 (en) 2020-05-27
EP4378457A2 (en) 2024-06-05
EP3525771A1 (en) 2019-08-21
US20190365740A1 (en) 2019-12-05
CA3044270A1 (en) 2018-05-24
WO2018094387A1 (en) 2018-05-24
US20210401832A1 (en) 2021-12-30
JP2024028652A (ja) 2024-03-04
JP2022059054A (ja) 2022-04-12
JP7474463B2 (ja) 2024-04-25

Similar Documents

Publication Publication Date Title
MY201629A (en) Benzopyrazole compounds and analogues thereof
TW201613887A (en) Antiproliferative compounds and methods of use thereof
PH12016502256A1 (en) Medical use
MY189333A (en) Pharmaceutical composition for use in prevention and/or treatment of disease that develops or progresses as a result of decrease or loss of activity of blood coagulation factor viii and/or activated blood coagulation factor viii
WO2015160975A3 (en) Combination of a pi3k inhibitor with a bcl-2 inhibitor for use in the treatment of cancer
MX2016015434A (es) Combinaciones farmaceuticas para tratar cancer.
MX365366B (es) Formulaciones tópicas y orales que comprenden taurina y magnesio para la prevención y el tratamiento del acné.
PH12017500444A1 (en) Pharmaceutical compositions comprising a dextromethorphan compound and quinidine for the treatment of agitation in dementia
EP4039247A3 (en) Sublingual formulation of riluzole
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
MX2017012123A (es) Combinaciones de un compuesto inhibidor de fosfoinositido 3-cinasa y un compuesto inhibidor de cdk4/6 para el tratamiento del cancer.
MX2021010297A (es) Inhibidores de calicreina plasmatica humana.
CY1119522T1 (el) (r)- πιρλινδολη και τα φαρμακευτικως αποδεκτα αλατα αυτης για χρηση στην ιατρικη
MX2019005782A (es) Prevencion y/o tratamiento de lesion aguda de riñon inducida por contraste.
MX2019002121A (es) Tratamiento conjunto para tratar el cancer de pancreas.
HK1243327A1 (zh) 包含螺旋藻和棕櫚酰基乙醇酰胺和/或其鹽或藥用上可接受衍生物的組合及其製劑，用於預防和/或治療過度活化的組織病症
HK1257590A1 (zh) 預防和治療藥物性腎損傷的藥物及其用途
MX2018006631A (es) Compuesto para uso en la prevencion y tratamiento de enfermedades neurodegenerativas.
PH12016502107A1 (en) Combination of brexpiprazole and nalmefene and use thereof for treating substance-related disorders
TH167850B (th) (r)-เพอร์ลินโดล และเกลือที่ยอมรับได้ทางเภสัชกรรมของมันสำหรับการใช้ ในยารักษาโรค
AR099490A1 (es) Métodos terapéuticos en los que se emplea noribogaína y compuestos relacionados
UA98964U (ru) Способ медико-психологической помощи больным сосудистой деменцией